The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Junichiro James Kazama

Division of Blood Purification Therapy

Niigata University Medical and Dental Hospital

Niigata

Japan

[email]@med.niigata-u.ac.jp

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Division of Blood Purification Therapy, Niigata University Medical and Dental Hospital, Niigata, Japan. 2002 - 2011
  • Department of Medicine, Division of Nephrology and Rheumatology, Niigata University, Niigata, Japan. 2001

References

  1. Nuclear chromatin-concentrated osteoblasts in renal bone diseases. Kazama, J.J., Yamamoto, S., Narita, I., Kurihara, S. Ther. Apher. Dial (2011) [Pubmed]
  2. A patient with severe hypercalcemia in multiple organ dysfunction syndrome: role of elevated circulating 1alpha,25(OH)2 vitamin D levels. Kazama, J.J., Yamamoto, T., Oya, H., Yamamoto, S., Sato, Y., Sakurada, J., Honda, T., Endoh, H., Narita, I. J. Bone Miner. Res. (2010) [Pubmed]
  3. Cancellous bone volume is an indicator for trabecular bone connectivity in dialysis patients. Kazama, J.J., Koda, R., Yamamoto, S., Narita, I., Gejyo, F., Tokumoto, A. Clin. J. Am. Soc. Nephrol (2010) [Pubmed]
  4. Oral phosphate binders: history and prospects. Kazama, J.J. Bone (2009) [Pubmed]
  5. Comparison of quantitative cancellous bone connectivity analyses at two- and three-dimensional levels in dialysis patients. Kazama, J.J., Koda, R., Yamamoto, S., Narita, I., Gejyo, F., Tokumoto, A. Calcif. Tissue Int. (2009) [Pubmed]
  6. The risk of gallbladder stone formation is increased in patients with predialysis chronic kidney disease but not those undergoing chronic hemodialysis therapy. Kazama, J.J., Kazama, S., Koda, R., Yamamoto, S., Narita, I., Gejyo, F. Nephron. Clin. Pract (2009) [Pubmed]
  7. Japanese Society of Dialysis Therapy treatment guidelines for secondary hyperparathyroidism. Kazama, J.J. Ther. Apher. Dial (2007) [Pubmed]
  8. Abeta-2M-amyloidosis and related bone diseases. Kazama, J.J., Yamamoto, S., Takahashi, N., Ito, Y., Maruyama, H., Narita, I., Gejyo, F. J. Bone Miner. Metab. (2006) [Pubmed]
  9. Circulating osteoprotegerin affects bone metabolism in dialysis patients with mild secondary hyperparathyroidism. Kazama, J.J., Omori, K., Yamamoto, S., Ito, Y., Maruyama, H., Narita, I., Gejyo, F., Iwasaki, Y., Fukagawa, M. Ther. Apher. Dial (2006) [Pubmed]
  10. Direct comparison between two 1-84PTH assays in dialysis patients. Kazama, J.J., Yamamoto, S., Kameda, S., Maruyama, H., Narita, I., Shigematsu, T., Gejyo, F. Nephron. Clin. Pract (2005) [Pubmed]
  11. Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kazama, J.J., Sato, F., Omori, K., Hama, H., Yamamoto, S., Maruyama, H., Narita, I., Gejyo, F., Yamashita, T., Fukumoto, S., Fukagawa, M. Kidney Int. (2005) [Pubmed]
  12. Maxacalcitol therapy decreases circulating osteoprotegerin levels in dialysis patients with secondary hyperparathyroidism. Kazama, J.J., Omori, K., Takahashi, N., Ito, Y., Maruyama, H., Narita, I., Gejyo, F., Iwasaki, Y., Fukagawa, M. Clin. Nephrol. (2005) [Pubmed]
  13. Role of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism. Kazama, J.J., Gejyo, F., Shigematsu, T., Fukagawa, M. Ther. Apher. Dial (2005) [Pubmed]
  14. Maxacalcitol is a possible less phosphatemic vitamin D analog. Kazama, J.J., Maruyama, H., Narita, I., Gejyo, F. Ther. Apher. Dial (2005) [Pubmed]
  15. Intact PTH assay overestimates true 1-84 PTH levels after maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism. Kazama, J.J., Omori, K., Higuchi, N., Takahashi, N., Ito, Y., Maruyama, H., Narita, I., Cantor, T.L., Gao, P., Gejyo, F. Nephrol. Dial. Transplant. (2004) [Pubmed]
  16. Osteoprotegerin and bone mineral metabolism in renal failure. Kazama, J.J. Curr. Opin. Nephrol. Hypertens. (2004) [Pubmed]
  17. Role of osteoclastic dysfunction in the development of renal bone disease. James Kazama, J., Gejyo, F., Kurosawa, T., Fukagawa, M. Nephrol. Dial. Transplant. (2003) [Pubmed]
  18. Circulating 1-84 PTH and large C-terminal PTH fragment levels in uremia. Kazama, J.J., Omori, T., Ei, I., Ei, K., Oda, M., Maruyama, H., Narita, I., Gejyo, F., Shigematsu, T., Fukagawa, M. Clin. Exp. Nephrol. (2003) [Pubmed]
  19. Development of hungry bone syndrome after rapid lowering of PTH with intravenous maxacalcitol therapy in a patient with non-uremic secondary hyperparathyroidism. Kazama, J.J., Suzuki, K., Yokoseki, A., Oyanagi, A., Goto, S., Shimada, H., Maruyama, H., Narita, I., Gejyo, F. Clin. Nephrol. (2003) [Pubmed]
  20. Microfocus computed tomography analysis of early changes in bone microstructure in rats with chronic renal failure. Kazama, J.J., Iwasaki, Y., Yamato, H., Murayama, H., Sato, M., Gejyo, F., Kurokawa, M., Fukagawa, K. Nephron Exp. Nephrol. (2003) [Pubmed]
  21. Serum cystatin C reliably detects renal dysfunction in patients with various renal diseases. Kazama, J.J., Kutsuwada, K., Ataka, K., Maruyama, H., Gejyo, F. Nephron (2002) [Pubmed]
  22. Osteoclastogenesis and osteoclast activation in dialysis-related amyloid osteopathy. Kazama, J.J., Maruyama, H., Gejyo, F. Am. J. Kidney Dis. (2001) [Pubmed]
 
WikiGenes - Universities